{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:40:44Z","timestamp":1772134844161,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2023,1,3]]},"DOI":"10.1038\/s41388-022-02532-2","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T17:03:19Z","timestamp":1668099799000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia"],"prefix":"10.1038","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2018-2342","authenticated-orcid":false,"given":"Alan","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Borot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert Mridul","family":"Grass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-7167","authenticated-orcid":false,"given":"Philip","family":"DeSouza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-6769","authenticated-orcid":false,"given":"Abdullah Mahmood","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2532_CR1","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.abg1209","volume":"372","author":"U Brinkmann","year":"2021","unstructured":"Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372:916\u20137.","journal-title":"Science"},{"key":"2532_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nbt.2016.12.010","volume":"39","author":"S Krah","year":"2017","unstructured":"Krah S, Sellmann C, Rhiel L, Schroter C, Dickgiesser S, Beck J, et al. Engineering bispecific antibodies with defined chain pairing. N. Biotechnol. 2017;39:167\u201373.","journal-title":"N. Biotechnol"},{"key":"2532_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","volume":"17","author":"H Li","year":"2020","unstructured":"Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020;17:451\u201361.","journal-title":"Cell Mol Immunol"},{"key":"2532_CR4","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.4049\/jimmunol.1501592","volume":"196","author":"J Golay","year":"2016","unstructured":"Golay J, Choblet S, Iwaszkiewicz J, Cerutti P, Ozil A, Loisel S, et al. Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies. J Immunol. 2016;196:3199\u2013211.","journal-title":"J Immunol"},{"key":"2532_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fimmu.2016.00394","volume":"7","author":"JH Ha","year":"2016","unstructured":"Ha JH, Kim JE, Kim YS. Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Front Immunol. 2016;7:394.","journal-title":"Front Immunol"},{"key":"2532_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/protein\/gzs064","volume":"25","author":"S Metz","year":"2012","unstructured":"Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel. 2012;25:571\u201380.","journal-title":"Protein Eng Des Sel"},{"key":"2532_CR7","doi-asserted-by":"publisher","first-page":"7630","DOI":"10.1074\/jbc.271.13.7630","volume":"271","author":"J de Kruif","year":"1996","unstructured":"de Kruif J, Logtenberg T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J Biol Chem. 1996;271:7630\u20134.","journal-title":"J Biol Chem"},{"key":"2532_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.4049\/jimmunol.148.5.1547","volume":"148","author":"SA Kostelny","year":"1992","unstructured":"Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol. 1992;148:1547\u201353.","journal-title":"J Immunol"},{"key":"2532_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1380-2933(97)00067-5","volume":"3","author":"A Pluckthun","year":"1997","unstructured":"Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 1997;3:83\u2013105.","journal-title":"Immunotechnology"},{"key":"2532_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41586-018-0802-y","volume":"565","author":"Z Chen","year":"2019","unstructured":"Chen Z, Boyken SE, Jia M, Busch F, Flores-Solis D, Bick MJ, et al. Programmable design of orthogonal protein heterodimers. Nature. 2019;565:106\u201311.","journal-title":"Nature"},{"key":"2532_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1535-6108(03)00057-6","volume":"3","author":"G Payne","year":"2003","unstructured":"Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell. 2003;3:207\u201312.","journal-title":"Cancer Cell"},{"key":"2532_CR12","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","volume":"44","author":"M Molhoj","year":"2007","unstructured":"Molhoj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, et al. CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol. 2007;44:1935\u201343.","journal-title":"Mol Immunol"},{"key":"2532_CR13","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.4049\/jimmunol.159.7.3372","volume":"159","author":"KH Roux","year":"1997","unstructured":"Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol. 1997;159:3372\u201382.","journal-title":"J Immunol"},{"key":"2532_CR14","doi-asserted-by":"crossref","unstructured":"Evans R, O\u2019Neill M, Pritzel A, Antropova N, Senior A, Green T et al. Protein complex prediction with AlphaFold-Multimer 2022: 2021.2010.2004.463034.","DOI":"10.1101\/2021.10.04.463034"},{"key":"2532_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","volume":"19","author":"M Mirdita","year":"2022","unstructured":"Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods. 2022;19:679\u201382.","journal-title":"Nat Methods"},{"key":"2532_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fonc.2018.00539","volume":"8","author":"D Schneider","year":"2018","unstructured":"Schneider D, Xiong Y, Hu P, Wu D, Chen W, Ying T, et al. A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia. Front Oncol. 2018;8:539.","journal-title":"Front Oncol"},{"key":"2532_CR17","doi-asserted-by":"publisher","first-page":"11978","DOI":"10.1073\/pnas.1819992116","volume":"116","author":"F Borot","year":"2019","unstructured":"Borot F, Wang H, Ma Y, Jafarov T, Raza A, Ali AM, et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc Natl Acad Sci USA 2019;116:11978\u201387.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2532_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70\u201382.","journal-title":"Protein Sci"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02532-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T10:04:20Z","timestamp":1672740260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02532-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,3]]}},"alternative-id":["2532"],"URL":"https:\/\/doi.org\/10.1038\/s41388-022-02532-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2135768\/v1","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"5 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Columbia University has granted an exclusive option to Brahma Therapeutics to license technology that is the subject of this study. AB, FB, AMA, and SM are co-inventors on pending patent applications filed by Columbia University and optioned to Brahma Therapeutics. SM has equity ownership and is on the Scientific Advisory Board of Brahma Therapeutics. MC, JD and PD is an employee of Brahma Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}